To determine who would benefit from TLR4 inhibition treatment for HCC prevention, we characterized using TCGA HCC public datasets, HCC patients with elevated TLR4 mRNA expression as well as HCC patients with elevated mRNA expression of two known cytokines produced by TLR4 activation, IL-6 and IL-10. Here, IL6 is linked to hepatocellular carcinoma.